greeksoup/ stock research

Utah Medical Products Inc.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 23 April 2026: press release. The quarter’s numbers.

Key takeaways

  • Sales and operating income fell: Sales were $8,722, down 10.2% from $9,710. Gross profit fell 4.6% to $5,282, operating income fell 18.7% to $2,565 and net income fell 14.4% to $2,604. Source
  • EPS fell less than net income: Diluted EPS was $0.818, down 11.0%. Fewer diluted shares, from repurchases, reduced the EPS decline relative to the net income decline. Source
  • Direct device sales fell 12.8%: Direct device sales made up 61% of domestic sales and fell $503 year on year, with all product categories lower. Source
  • Domestic Filshie sales jumped: Domestic Filshie device sales rose $493, or 47.4%, to 28% of domestic sales. Management described this as an abnormally high U.S. medical facility demand quarter. Source
  • Outside-US sales fell 23.4%: Outside-US sales were $3,162, $965 lower. Excluding the China distributor, the decline was $176, mainly lower Filshie Clip System sales. Source
  • China and PendoTECH sales absent: Sales to the former China distributor and to PendoTECH totalled $857 in 1Q 2025, 87% of the lower quarter-on-quarter sales. None occurred in 1Q 2026. Source
  • Gross margin rose to 60.6%: Gross margin was 60.6% against 57.0%. Management said the absence of sales to the former China distributor, which carried a low margin, helped the average. Source
  • G&A rose on health costs and litigation: G&A was $2,044, or 23.4% of sales. The increase came from U.S. health care costs up $147, litigation up $127 and a weaker USD effect on foreign G&A. Source
  • Cash and investments rose: Cash and investments reached $87,406, up $1,649 from year-end, after $129 of repurchases, $989 of dividends and $130 of equipment purchases. Source

“Sales were lower in all product categories in what was hopefully just an abnormally weak demand quarter.”

Utah Medical Products Inc., press release

Guidance

AreaPeriodFigureAgainst last quarter
Litigation expense Source2026 full yearlower than 2025 level
U.S. G&A health care costs Sourceremainder of 2026more like 2025 experience

What changed from last quarter

  • Guidance kept: Management said 1Q 2026 results were consistent with the projections previously announced for calendar 2026. Source
  • New: Court dismissals in the litigation rose to 15 of 19 cases, up from 14 of 19 reported in January 2026. Source

Headline results and earnings per share

  • Sales and operating income fell: Sales were $8,722, down 10.2% from $9,710. Gross profit fell 4.6% to $5,282, operating income fell 18.7% to $2,565 and net income fell 14.4% to $2,604. Source
  • EPS fell less than net income: Diluted EPS was $0.818, down 11.0%. Fewer diluted shares, from repurchases, reduced the EPS decline relative to the net income decline. Source
  • Operating and net margins narrowed: Operating margin was 29.4% against 32.5%, EBT margin 36.5% against 39.7%, and net margin 29.9% against 31.3% in 1Q 2025. Source

Domestic sales and product lines

  • Domestic sales were nearly flat: Domestic sales were $5,560 against $5,583, 0.4% lower. Management said domestic sales were about the same in both periods. Source
  • Direct device sales fell 12.8%: Direct device sales made up 61% of domestic sales and fell $503 year on year, with all product categories lower. Source
  • Domestic Filshie sales jumped: Domestic Filshie device sales rose $493, or 47.4%, to 28% of domestic sales. Management described this as an abnormally high U.S. medical facility demand quarter. Source
  • OEM sales slightly lower: Domestic OEM sales fell $13, or 2.1%, after the final PendoTECH order backlog shipped in 1Q 2025. Source

“UTMD continues to effectively manage its variable manufacturing expenses.”

Utah Medical Products Inc., press release

Outside-US sales, customers and currency

  • Outside-US sales fell 23.4%: Outside-US sales were $3,162, $965 lower. Excluding the China distributor, the decline was $176, mainly lower Filshie Clip System sales. Source
  • China and PendoTECH sales absent: Sales to the former China distributor and to PendoTECH totalled $857 in 1Q 2025, 87% of the lower quarter-on-quarter sales. None occurred in 1Q 2026. Source
  • Filshie sales lower in three countries: Direct Filshie sales to medical facilities in Canada, France and Australia were $230 lower, while Ireland and UK direct sales were about the same. Source
  • Currency lifted reported OUS sales: A weaker USD added $169 to reported OUS sales. On a constant currency basis, OUS sales were $1,133, or 27.5%, lower. Source

Gross margin, overhead and tariffs

  • Gross margin rose to 60.6%: Gross margin was 60.6% against 57.0%. Management said the absence of sales to the former China distributor, which carried a low margin, helped the average. Source
  • Gross profit fell less than sales: Gross profit fell $256, or 4.6%, against 10.2% lower sales, reflecting product mix and a one-time standard cost adjustment. Source
  • Tariffs on Filshie devices rose: Tariffs paid on Filshie devices bought from UTMD’s own Irish subsidiary rose $108, which management said had the effect of raising the U.S. federal tax rate. Source
  • Overhead rose on lower sales: Manufacturing overhead rose, mainly from cost-of-living adjustments for employees. Management said higher overhead with lower sales reduces gross margin. Source

“The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.”

Utah Medical Products Inc., press release

Operating costs and litigation

  • Operating expenses rose $332: Operating expenses were $2,717, or 31.1% of sales, against $2,385, or 24.6%. Most of the increase came from G&A expenses. Source
  • G&A rose on health costs and litigation: G&A was $2,044, or 23.4% of sales. The increase came from U.S. health care costs up $147, litigation up $127 and a weaker USD effect on foreign G&A. Source
  • Sales and marketing rose modestly: S&M was $519, or 5.9% of sales, against $500, or 5.1%. Management said more than half the percentage rise reflects lower sales. Source
  • R&D flat in dollars: R&D was $154, or 1.8% of sales, against $155, or 1.6%, in 1Q 2025. Source

Tax, non-operating income and share count

  • Lower tax rate cushioned profit: The tax provision was 18.2% of pretax income, against 21.2%, reflecting the mix of profits across sovereignties. Source
  • Interest income fell: Net non-operating income was $617, against $705, due to lower interest earned on cash balances. Source
  • Repurchases continued at low volume: UTMD repurchased 2,196 shares at $58.58 in 1Q 2026, against 54,267 shares at $59.35 a year earlier. Shares outstanding ended the quarter at 3,184,025. Source

Cash, balance sheet and dividends

  • Cash and investments rose: Cash and investments reached $87,406, up $1,649 from year-end, after $129 of repurchases, $989 of dividends and $130 of equipment purchases. Source
  • Equity and working capital rose: Stockholders’ equity was $120.4 million, up $1.1 million in the quarter despite dividends and repurchases. Working capital rose $1,730 from year-end, and the current ratio was 28.6. Source
  • Dividends paid at $0.31 a share: Dividends of $989, or $0.31 a share, were paid in 1Q 2026, against $1,017 at $0.305 a share a year earlier. Source
  • Inventories rose from year-end: Inventories rose $787 from year-end and $75 from a year earlier. Receivable days were 37.5, which management said is well within its targets. Source

Coming up, as management said on 23 April 2026

  • Repurchase effect on share count in 2Q: Management said the full antidilution effect of 1Q 2026 repurchases will show in 2Q 2026, because of the time-weighted share calculation. Source

Figures management reported

FigureReported
Direct medical device sales (domestic) Source$503 lower (12.8%); 61% of domestic sales
Domestic Filshie device sales Source$493 higher (+47.4%); 28% of domestic sales
OUS sales invoiced in foreign currencies Source$2,327 (74% of OUS sales)

Risks management discussed

  • Regulatory: Expected lower litigation expense depends on no case going to trial. Source
  • Operational: Self-insured health costs can rise sharply when a major claim occurs, and management said they are not predictable. Source
  • External: Reported sales are affected by currency moves; constant currency total sales were 11.9% lower than a year earlier. Source

Earlier plans management reported on

  • Met: Management said the company had no sales to the former China distributor or PendoTECH in 1Q 2026, as previously reported. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.